Clinical Trials at Kaiser Permanente-San Francisco
As of June 2026, 38 paid clinical trials are recruiting at Kaiser Permanente-San Francisco, located at 2425 GEARY BLVD, SAN FRANCISCO, CA 94115-3358, phone (415) 833-4515 in San Francisco, California. Active studies at this site cover conditions such as Breast Cancer, Prostate Cancer and Heart Failure. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
38 clinical trials at Kaiser Permanente-San Francisco
·Clear filters·↓ Download CSVShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
E-Mindfulness Approaches for Living After Breast Cancer
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
An Internet-based Program to Help Cancer Survivors Manage Pain
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
About research studies in San Francisco
San Francisco has approximately 1,434 recruiting research studies across a wide range of therapeutic areas. California hosts a dense network of world-class research institutions, including UC San Diego Health, Stanford Medicine, UCLA Health, UCSF, City of Hope, and Scripps Research. The state's thriving biotech corridor and diverse patient population make it a national hub for both early-phase and late-phase clinical research.
Common conditions studied in San Francisco
- Breast Cancer (28 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Prostate Cancer (27 active studies). Prostate cancer studies test next-generation hormone therapies, PARP inhibitors, and radioligand treatments for both localized and advanced disease.
- Heart Failure (18 active studies). Heart failure trials explore SGLT-2 inhibitors, novel myosin modulators, and device-based therapies for both reduced and preserved ejection fraction.
- HIV (16 active studies). HIV trials investigate long-acting injectable antiretrovirals, broadly neutralizing antibodies, and cure-focused strategies.
- Cancer (15 active studies). Recruiting Cancer studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Glioblastoma (15 active studies). Glioblastoma studies investigate tumor-treating fields, targeted small molecules, and immunotherapy combinations for this aggressive brain cancer.
Leading research sponsors in San Francisco
- University of California, San Francisco
- Power Life Sciences Inc.
- National Cancer Institute (NCI)
- AstraZeneca
- Children's Oncology Group
Local regulations and guidelines
Clinical trials in California are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. In addition, California-specific protections such as the California Consumer Privacy Act (CCPA) and the Confidentiality of Medical Information Act (CMIA) impose stringent data-privacy requirements on research involving California residents.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in San Francisco. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in San Francisco
Hipa.ai aggregates every recruiting study in San Francisco from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in San Francisco?
There are approximately 1,434 recruiting clinical trials in San Francisco, California listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in San Francisco pay participants?
Most recruiting trials in San Francisco compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in San Francisco?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in San Francisco?
The most common conditions under active study in San Francisco include Breast Cancer (28), Prostate Cancer (27), Heart Failure (18), HIV (16), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in San Francisco?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in San Francisco on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in San Francisco?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in San Francisco?
Recruiting research sites in San Francisco include University of California, San Francisco, University of California San Francisco, Power Life Sciences, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in San Francisco right now?
The largest active categories in San Francisco are Cancer & tumors (432), Cardiovascular (91), Neurology & pain (81). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Kaiser Permanente-San Francisco?
Kaiser Permanente-San Francisco is located at 2425 GEARY BLVD, SAN FRANCISCO, CA 94115-3358. Use the Google Maps link in the intro above to get directions.
How do I contact Kaiser Permanente-San Francisco?
You can reach Kaiser Permanente-San Francisco by phone at (415) 833-4515. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.